@WeedStreet420 Not many, and the ones that didn’t come back went down on balance sheets they couldn’t fix.
$GLAS went down on a trim mix, a delayed filing and an auditor fight. That’s a different problem than insolvency. Whether they fix it is the part worth debating.
I was bullish on $GLAS at $10. I was wrong, and I'm not going to dress that up. You get it wrong, you own it, you dust yourself off, and you keep working. That's the job.
But being wrong on the entry doesn't necessarily mean being wrong on the business. I listened to last night's call in full.
Start with governance, because that's where so much of the noise has been.
Kazan said the multiple-voting shares expire at the end of June 2027 and he does not intend to ask the board or shareholders to extend them. If that happens, a major source of concentrated voting control disappears.
He also went through the related-party arrangements one by one.
The Beachfront consulting agreement, which he controls through the Kazan Trust, was terminated September 18. The company acquired the remaining interest in the Lampo property in August 2025, eliminating the NeoStreet related-party lease.
The Delavana lease was already terminated, with remaining payment obligations ceasing October 1.
The headquarters lease now has a 30-day termination option in the company's favor. Insurance brokerage services are going out to RFP, with a non-related vendor expected by year-end.
These aren't just promises to improve governance. Several changes have already happened. Others still need to be completed.
I have no interest in personal attacks on the directors. I care about execution and where the business goes from here.
The auditor story also made more sense once explained.
MGO resigned in September at the company's request so BDO could come in, chosen partly because BDO said it could meet the November 16 deadline. In mid-October, BDO indicated it hadn't finished reviewing the deconsolidation accounting and raised the possibility of filing Q3 without a completed review.
Management found that unacceptable and returned to MGO, which had already reviewed the Q2 deconsolidation accounting without requiring material modifications.
BDO characterized its unfinished review as an unresolved issue under Canadian disclosure rules. The company disagrees but disclosed BDO's position anyway. BDO never issued an audit or review report during its tenure.
The rapid auditor turnover still deserves scrutiny. But the company has now explained the sequence and reported on schedule.
Then the operations.
Flower yields versus their own historical best quarters:
Q2: −25%
Q3: −10%
Q4 to date: ~−5%
Production cost per pound:
Q1: $175
Q2: $122
Q3: $109
Meanwhile, quarterly biomass production reached a record 319,000 pounds.
The cogeneration unit was offline throughout Q3. No supplemental CO2 and insufficient power to run all the Greenhouse 2 lights. Management expects it back online this week.
Roughly 60 days to grow, another 30 to process, and additional time to sell. Those benefits aren't reflected in the reported numbers yet.
They also paused hemp. Management acknowledged disappointing economics alongside regulatory uncertainty. I'd rather see them concentrate capital on restoring their core business than keep funding an initiative that isn't delivering, especially with the next phase of federal hemp restrictions expected December 11.
Could they have communicated better through all of this? Absolutely. The uncertainty between the October preliminary release and last night's call didn't help investor confidence. But @grahamfarrar stepped up last night, faced the tough questions head-on, and answered them to my satisfaction.
Looking in the rearview mirror and pointing fingers has never made me much money.
Looking forward, management says it has no plans for further ATM issuance beyond October. If that holds, a source of potential dilution and selling pressure is removed.
Management also says its $39.7 million in cash and restricted cash is sufficient to execute the plan, including $20 million of capex, through the seasonally weakest cash period in the first half of 2027. That's the financial runway I'll be watching.
Greenhouse 2 is operating. Production costs have fallen sharply. Flower yields are recovering.
And Glass House appears on FTSE Russell's official preliminary additions list for the Russell 3000, with reconstitution scheduled to become effective after the December 11 close. It's preliminary, not guaranteed, but another development worth watching.
Q4 margins are expected to remain roughly flat, with an improving product mix offset by seasonally weaker flower prices. The real financial test comes in Q1 2027.
What would make me wrong?
Flower yields stop recovering. Seasonal pricing doesn't improve. The company needs substantially more capital than anticipated. Or the DEA's interpretation of California medical cannabis licensing creates broader obstacles than management expects.
Those are real risks.
And there's a broader implication for $MSOS and the cannabis sector. Glass House's collapse has contributed to negative sentiment across an already battered industry. If $GLAS can demonstrate that its operational turnaround is real, it could go from being part of the problem to part of the recovery. A rising tide lifts all boats, and this sector could certainly use one.
Not advice. Just a guy thinking out loud.
The most interesting thing from tonight's $GLAS call may be getting overlooked.
@grahamfarrar said the DEA show-cause letters have not gone to medical-only operators, but rather operators with both medical and adult-use licenses.
Here's why the distinction matters:
Glass House's June deconsolidation separated its dual-use retail business from its medical cannabis operations. The company says its remaining operations are medical-only and registered with the DEA.
If that distinction holds as the DEA process unfolds, the recent regulatory actions may be less threatening to GLAS's specific structure than the markets have been pricing in.
There are still unresolved questions about California's medical patient-certification requirements, and none of this guarantees federal approval or interstate exports.
Meanwhile, the operational recovery is getting overlooked.
Flower yields versus historical best:
Q2: −25%
Q3: −10%
Q4 to date: ~−5%
Production cost/lb:
Q1: $175
Q2: $122
Q3: $109
Management expects the offline cogeneration unit to restart this week.
Q4 margins are expected to remain roughly flat due to seasonal pricing. The real test of the recovery comes in Q1 2027.
The regulatory uncertainty is real. So is the operational progress.
Wouldn't surprise me to see $GLAS bungee back up from here, given how much negativity is already priced in.
Not advice, just my observations from the call.
@srg444 Adding one to @srg444’s list: the spread.
Q3'25: $155 ASP, $128 cost. $27/lb on 124K lbs.
Q3'26: $151 ASP, $109 cost. $42/lb on 319K lbs.
About $3M of gross spread to $13M, and $GLAS did it with price down.
$95/lb target reaffirmed. That math gets interesting.
BREAKING: Massachusetts voters have overwhelmingly rejected a first-in-the-nation ballot measure that would have repealed legal recreational marijuana sales. https://t.co/ycfcIKk5fX
👀👀👀
Democratic U.S. Senate candidate James Talarico said he wants to partner with President Donald Trump on legalizing marijuana if he wins next month's election.
"He's for legalizing marijuana, and so am I. I hope we can do that together and expunge the records of people who have been locked up for a crime that doesn't hurt anybody."
https://t.co/hw1DtIAnAU
The City Council in Worcester, Massachusetts’ second-largest city, voted unanimously tonight to oppose Question 8, which would repeal legal recreational marijuana sales statewide. https://t.co/C5UTgG8UY4
The biggest killer on the planet is stress, and I’ve always believed in the medicinal benefits of the cannabis plant. That’s why I support the new CMS Innovation Center initiative expanding clinician-guided access to hemp-derived cannabinoid products. It’s an important step toward learning more about how these plant-based remedies can improve the health and quality of life of older Americans.
I get that, but just to clarify: “2026-27” is the federal fiscal year, which started October 1, 2026.
This isn’t a policy scheduled for sometime in 2027.
Treasury and the IRS have made 280E guidance an active priority now for the current fiscal year.
There’s no hard deadline, but the work is already on the agenda and resources are being committed to it.
So I’d read this less as “wait until 2027” and more as “the implementation work is officially underway.”
(Let’s see if the document actually attaches this time)
While everyone was focused on the ALJ stay this week, Treasury and the IRS quietly did something more interesting.
On September 29, the same day as the stay, they formally made Section 280E guidance an official federal priority for 2026-27. It wasn't on last year's list at all. Now it's one of 121 projects they've committed resources to for the fiscal year.
This isn't housekeeping.
Treasury has already said it expects a transition rule generally treating the April scheduling change as applying for the entire taxable year in which it took effect. For calendar-year filers that could mean qualifying medical activity gets relief back to January 1, not April 22.
They're also writing guidance for companies running both medical and adult-use operations, including how to apportion expenses between activities still subject to 280E and those that aren't. For the MSOs that make up $MSOS, that's one of the biggest practical questions hanging over the sector since April.
Worth being clear about the limits. Inclusion sets no deadline. It doesn't eliminate 280E for anyone. And all of it is written against the April order, which is under challenge in the D.C. Circuit.
Within 24 hours, one part of the government paused a proceeding over a report about written procedures. Another committed to building the tax plumbing that makes the reform already on the books actually function.
Only one of those got any attention.
Not advice. Just a guy thinking out loud.
https://t.co/3vdeC34WvB
Weird couple of weeks. I feel better about this industry than I have in a long time and everyone I talk to sounds miserable. I can't square those.
Start with the stay, since that's what everyone locked onto. Judge Julius paused the proceeding to decide whether a GAO report belongs in the record. He didn't admit it. He didn't authorize briefing. He said nothing about marijuana's merits. DEA responds by October 13.
I get why that reads badly after a year of waiting. But one of the groups that filed that motion is also a petitioner in the D.C. Circuit case against the April order. These people have spent two years hunting for a procedural crack. If this record goes up with a shortcut in it, that's their appeal, and we're still arguing in 2029. Take the two weeks.
The other thing I can't shake is how much weight $MSOS is carrying in these conversations. It's a sentiment barometer. It tells you how a small, well-funded group of institutions felt about a headline on a given afternoon. It doesn't tell you whether the tax rules are getting written or whether a state just cleared an obstacle. Those move slowly and don't print a ticker, so nobody discusses them.
Here's what happened over the last two or three weeks while everyone watched the chart.
Treasury and the IRS put Section 280E guidance on their 2026-27 Priority Guidance Plan. It wasn't on last year's list at all. That's staff assigned to transition year treatment and expense apportionment for mixed operators, which is what determines whether any of this reaches a real business.
Alabama's public health committee unanimously withdrew its objection to rescheduling. One fewer state in the road.
The CLAIM Act was introduced in the House, joining a Senate version from July. Underinsurance is a real cost-of-capital problem nobody talks about. Raskin and Nunn also filed the CURE Act so past cannabis use stops killing federal security clearances.
New York did $512.6 million in Q3. Record quarter, $1.41 billion this year, $4.1 billion program to date, 1,039 licensed retailers. Two years ago people were writing that market's obituary. They also pushed the provisional dispensary deadline out to the end of 2028, which matters if you were staring down a cliff in ninety days.
Missouri proposed opening ownership to public companies.
Virginia put out draft adult-use rules.
Minnesota is running workforce training.
And 34 marijuana and hemp measures are sitting in Congress.
The stay was a setback and anyone telling you otherwise is selling something. But it got all the oxygen while a federal tax agency assigned staff, a state dropped its objection, a billion-dollar market printed a record, and four more kept grinding on the plumbing.
That's a reasonable stretch by any standard I've got.
Enjoy the weekend everyone!
*as always, not advice, just a guy thinking out loud.
@cmarttrades@TheCrusaderDeux Good one, and I’m sure I missed so many more. I hope people keep posting them here in the comments to highlight all the progress being made.
@WeedStreet420 I saw you post a screenshot of this website about six months ago, and I've run my own posts through it a few times to verify, only to have it say what I wrote was AI as well. I'd look into your site.
Fair clarification on what you meant by “removed from the CSA.” We agree there: 280E applies to Schedule I/II, not Schedule III.
Where I disagree is calling the guidance a nothing-burger. Of course IRS isn’t creating the law. But transition-year treatment and expense allocation for mixed medical/adult-use businesses are real questions Treasury has specifically said it intends to address.
So yes, it’s guidance. But guidance on how companies actually apply a major tax change is still meaningful.